Literature DB >> 29021868

Management of patients with long QT syndrome.

Serkan Cay1, Ozcan Ozeke1, Firat Ozcan1, Serhat Koca2, Aysenur Pac2, Dursun Aras1, Serkan Topaloglu1.   

Abstract

Entities:  

Year:  2017        PMID: 29021868      PMCID: PMC5634716          DOI: 10.1016/j.joa.2017.07.002

Source DB:  PubMed          Journal:  J Arrhythm        ISSN: 1880-4276


× No keyword cloud information.
I have read with great interest the case report entitled “Epicardially placed implantable cardioverter-defibrillator for a child with congenital long QT syndrome” by Sugiyama et al. in the latest issue of the journal [1]. The authors well presented a case of long QT syndrome managed using implantation of an epicardial shock electrode and dose titration of beta-blocker therapy. However, some important issues should be mentioned. As compared to beta-blocker therapy with metoprolol, treatment with nadolol has been shown to significantly decrease breakthrough cardiac events in symptomatic patients [2]. Furthermore, the therapeutic efficacy of nadolol was better in patients with long QT syndrome, particularly in LQT2 [3], [4]. An implantable cardioverter–defibrillator should be considered early in the diagnosis of patients with recurrent symptoms despite receiving beta-blocker therapy, although inherent difficulties are related to much smaller body weight, body surface area, and continued growth of children. Another limitation of high-dose beta blocker therapy is that negative chronotropic effects resulted in potential device pacing attempts, which can cause atrial arrhythmias and left ventricular dysfunction with long-term atrial and ventricular pacing, respectively. Single-coil defibrillator lead implanted at the free wall, using an active can, might be an alternative approach (Fig. 1). Last, device programming using high counts with initial detection, upper threshold levels >250 bpm with a single detection zone and maximum shock output, and features minimizing ventricular pacing should be considered in all patients with inherited arrhythmia syndromes.
Fig. 1

Direct radiography shows abdominally located active can and epicardially implanted single-coil defibrillator lead (arrow) with pacing and sensing electrodes (arrow heads) on postero-anterior (a) and left-lateral (b) projections. Epicardially implanted single-coil electrode seen on the beating heart (c).

Direct radiography shows abdominally located active can and epicardially implanted single-coil defibrillator lead (arrow) with pacing and sensing electrodes (arrow heads) on postero-anterior (a) and left-lateral (b) projections. Epicardially implanted single-coil electrode seen on the beating heart (c).

Conflict of interest

All authors declare no conflict of interest related to this study.
  4 in total

1.  Efficacy of different beta-blockers in the treatment of long QT syndrome.

Authors:  Abeer Abu-Zeitone; Derick R Peterson; Bronislava Polonsky; Scott McNitt; Arthur J Moss
Journal:  J Am Coll Cardiol       Date:  2014-09-30       Impact factor: 24.094

Review 2.  Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent?

Authors:  Michael J Ackerman; Silvia G Priori; Anne M Dubin; Peter Kowey; Nicholas J Linker; David Slotwiner; John Triedman; George F Van Hare; Michael R Gold
Journal:  Heart Rhythm       Date:  2016-09-19       Impact factor: 6.343

3.  Epicardially placed implantable cardioverter-defibrillator for a child with congenital long QT syndrome.

Authors:  Hirotaro Sugiyama; Motomi Tachibana; Hiroshi Morita; Nobuhiro Nishii; Akihito Miyoshi; Hiroyasu Sugiyama; Koji Nakagawa; Atsuyuki Watanabe; Kazufumi Nakamura; Hiroshi Ito
Journal:  J Arrhythm       Date:  2016-11-10

4.  Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol.

Authors:  Priya Chockalingam; Lia Crotti; Giulia Girardengo; Jonathan N Johnson; Katy M Harris; Jeroen F van der Heijden; Richard N W Hauer; Britt M Beckmann; Carla Spazzolini; Roberto Rordorf; Annika Rydberg; Sally-Ann B Clur; Markus Fischer; Freek van den Heuvel; Stefan Kääb; Nico A Blom; Michael J Ackerman; Peter J Schwartz; Arthur A M Wilde
Journal:  J Am Coll Cardiol       Date:  2012-10-17       Impact factor: 24.094

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.